⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 4, 2024Scandinavian Journal of Rheumatology

Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort

Nicola Farina Alessandro Tomelleri Nicola Boffini A. Cariddi Stefania Calvisi N. Viapiana Elena Baldissera Marco Matucci‐Cerinic Lorenzo Dagna

View Full Paper

Ask AI

Bookmark

Share

Abstract

The efficacy of Janus kinase inhibitors (JAKi) in rheumatoid arthritis (RA) has been clearly shown. However, information on comparative drug retention rates (DRRs) of different JAKi is heterogeneous. The aim of this study was to compute and compare DRRs of different JAKi in a large cohort of RA patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Farina et al. (2024) studied this question.

synapsesocial.com/papers/68e66361b6db6435875f02de https://doi.org/10.1080/03009742.2024.2353433

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort2024 · 7 citations
2Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study2025
3Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study2025 · 1 citations
4Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis2024 · 11 citations
5Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study2024 · 16 citations